Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Keywords:
Dabrafenib
Inhibitor of mutated BRAF,
Metastatic melanoma
Note:
All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.
Citation:
Hauschild, A. (A.); Grob, J.J. (Jean-Jacques); Demidov, L.V. (Lev V.); et al. "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial". The Lancet. 380 (9839), 2012, 358 - 365
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.